Most conventional approaches for capturing CTCs use an EpCAM-based enrichment strategy, which does not work well in cancers that show low or no expression of EpCAM, such as renal cell carcinoma (RCC). The gene discussed is EPCAM; the disease is hereditary clear cell renal cell carcinoma.